Drug Manufacturing

Mirum and Incyte’s Atebrioz approved for FOP in US

The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 years and above.

Resilience and Lilly to increase US medicines production with $750m investment

Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly’s KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US.

BeOne to invest $300m in US manufacturing facility expansion

BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

Redefining Safety, Efficiency, and Sustainability: SCHOTT Pharma Launches Next-Generation Polymer Syringe System

SCHOTT Pharma, a pioneer in drug containment and delivery solutions, launches the next generation of SCHOTT TOPPAC® infuse polymer syringes, a system designed to improve safety, efficiency, and sustainability in healthcare.

Cellares and TScan to assess automated manufacturing of TSC-101 therapy

Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

Telix and Regeneron to co-develop radiopharmaceutical therapies

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies.

Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP).

CordenPharma leases space at Flatiron Park for peptides development

US-based CordenPharma Colorado has leased a 64,000ft² space at BioMed Realty’s Flatiron Park’s 5505 Central, which marks Boulder’s first purpose-built speculative lab building, for peptides development.

NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD

NorthX Biologics and Demeetra have entered a strategic partnership focused on integrated cell line development (CLD) and good manufacturing practice (GMP) manufacturing.